A retrospective analysis of the experimental and clinical study of the antiviral herbal drug flakozid in viral infections characterized by lesions of the skin and mucous membranes
- Authors: Karabaeva V.V.1, Krepkova L.V.1, Babenko A.N.1, Mizina P.G.1, Shutkina S.M.2
-
Affiliations:
- All-Russian Scientific Research Institute of Medicinal and Aromatic Plants
- Branch of the FSBI "52 CDС" of the Ministry of Defense of Russia
- Issue: Vol 27, No 12 (2024)
- Pages: 110-117
- Section: Problems of experimental biology and medicine
- URL: https://ogarev-online.ru/1560-9596/article/view/276735
- DOI: https://doi.org/10.29296/25877313-2024-12-14
- ID: 276735
Cite item
Open Access
Access granted
Subscription Access
Abstract
Introdction. Herpesvirus infections are one of the leading medical and social problems and are defined as a "global problem of humanity". Currently, the most common are simple (HSV-1, HSV-2) and herpes zoster (VVO). For the prevention and treatment of herpesvirus infections, antiviral drugs are prescribed, one of which is the herbal drug Flakozid, 0.1 g tablets for oral administration.
The aim of the work was a retrospective analysis of the results of an experimental and clinical study of Flakozid in simple recurrent and herpes zoster, chickenpox.
Material and methods. The antiviral properties of Flakozid were studied in in vitro experiments, in the culture of chicken embryo fibroblast cells against three strains of herpes virus (2 strains geratogenic "10", "90" and dermatogenic strain "64") and in vivo − on a model of experimental herpetic encephalitis of white mice in doses from 20 mg/kg to 500 mg/ kg with the administration of per os and subcutis. The results of the clinical study of Flakozid were analyzed in 313 patients (adults and children) with simple recurrent herpes 202 patients, including genital – 65, with herpes zoster – 45, chickenpox – 66. The criteria for the effectiveness of antiviral therapy of herpes were the duration of inflammatory phenomena, a reduction in the number and duration of relapses; in chickenpox – the severity of symptoms of intoxication, the nature and spread of rashes, the degree of their reverse development. Flakozid was prescribed 0.2–0.6 g per day.
Results. Experimental studies have shown that Flakozid had a high viral inhibitory effect against Herpes simplex. Treatment with Flakozid led to a high therapeutic effect: complete resolution of rashes in simple recurrent herpes after an average of 6-14 days, genital – 8-15 days, shingles – 7-15 days and shortening the duration of relapses by 2 times. The therapeutic effect of Flakozid in the treatment of genital herpes was noted in 91.6% of cases and exceeded the effect of Alpizarin (40%); in chickenpox –74%.
Conclusions. The high therapeutic effect of Flakozid in the treatment of viral infectious and inflammatory dermatoses in adults and children allowed it to be recommended in a wide clinical practice in the treatment of simple recurrent herpes, including genital and extragenital localization; herpes zoster, chickenpox.
Full Text
##article.viewOnOriginalSite##About the authors
V. V. Karabaeva
All-Russian Scientific Research Institute of Medicinal and Aromatic Plants
Author for correspondence.
Email: vera-karabaeva@rambler.ru
ORCID iD: 0000-0002-0259-5306
Internist, Senior Research Scientist, Department of Experimental Pharmacology
Russian Federation, 7/1, Green str., Moscow, 117216L. V. Krepkova
All-Russian Scientific Research Institute of Medicinal and Aromatic Plants
Email: krepkowa2011@yandex.ru
ORCID iD: 0000-0002-3580-336X
Ph.D. (Biol.), Head of Toxicology Department
Russian Federation, 7/1, Green str., Moscow, 117216A. N. Babenko
All-Russian Scientific Research Institute of Medicinal and Aromatic Plants
Email: alexandra.mogileva@gmail.com
ORCID iD: 0000-0001-9629-5525
Ph.D. (Biol.), Leading Research Scientist, Toxicology Department
Russian Federation, 7/1, Green str., Moscow, 117216P. G. Mizina
All-Russian Scientific Research Institute of Medicinal and Aromatic Plants
Email: pg-mizina@vilarnii.ru
ORCID iD: 0000-0001-6510-9603
Dr.Sc. (Pharm.), Professor, Advisor to the Director, Honored Scientist of the Russian Federation
Russian Federation, 7/1, Green str., Moscow, 117216S. M. Shutkina
Branch of the FSBI "52 CDС" of the Ministry of Defense of Russia
Email: svetlana.shutkina1979@mail.ru
Internist, FSBI «52KDC» of the Russian Ministry of Defense
Russian Federation, 3/3; Planetnaya str., Moscow, 125167References
- Vsemirnaja organizacija zdravoohranenija. Virus prostogo gerpesa. Informacionnyj bjulleten'. 05.04. 2023. [Jelektronnyj resurs]. Rezhim dostupa:https://www.who.int/ru/news-room/fact-sheets/detail/herpes-simplex-virus.
- Isakov V.A., Isakov D.V. Novye aspekty patogeneza prostogo gerpesa (obzor). Vestnik gematologii. 2016; 4(XII):4-9. (In Russ.).
- Gerpecvirusnye infekcii cheloveka (2-e izd., pererab., dop.): Rukovodstvo dlja vrachej /Pod redakciej professora V.A. Isakova. SPb., SpecLit. 2013. 670 s (In Russ.).
- Shul'zhenko A.E., Shhubelka R.V., Zujkova I.N. Gerpesvirusnye infekcii. Sovremennyj vzgljad na problemu. 2022. 344 s. (In Russ.).
- Omarova S., Cannon A., Weiss W. et al. Genital Herpes Simplex Virus-An Updated Review. Adv Pediatr. 2022 Aug; 69(1):149–162. doi: 10.1016/j.yapd.2022.03.010. Epub 2022 Jun 21.
- Klinicheskie rekomendacii. Anogenital'naja gerpeticheskaja virusnaja infekcija, god utverzhdenija 2023. (In Russ.).
- Schuppe H.C., Meinhardt A., Allam J.P. et al. Chronic orchitis: a neglected cause of male infertility? Andrologia. 2008; 40: 84–91. doi: 10.1111/j.1439-0272.2008.00837.x.
- Kuhanova M.K., Korovina A.N., Kochetkov S.N. Virus prostogo gerpesa cheloveka: zhiznennyj cikl i poisk ingibitorov. Uspehi biologicheskoj himii, 2014;54:457–494. (In Russ.).
- Vikulov G.H. Immunologicheskie aspekty gerpesvirusnyh infekcij. Klinicheskaja dermatologija i venerologija. 2015; 5: 104–114. (In Russ.).
- O sostojanii sanitarno-jepidemiologicheskogo blagopoluchija naselenija v Rossijskoj Federacii v 2022 godu: Gosudarstvennyj doklad. M.: Federal'naja sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchija cheloveka, 2023. 368 s. (In Russ.).
- Tamrazova O.B., Teben'kov A.V., Ermakova M.N. Novoe naruzhnoe sredstvo dlja lechenija gerpeticheskih vysypanij. Pediatrija. 2012; 1: 17–22. Prilozhenie consilium medicum. (In Russ.).
- Kaira A. N., Lavrov V. F. Vetrjanaja ospa i opojasyvajushhij gerpes. Uchebnoe posobie. Moskva. 2020: 8. (In Russ.).
- Bogojavlenskij A.P., Turmagambetova A.S., Berezin V.Je. Protivovirusnye preparaty rastitel'nogo proishozhdenija. Fundamental'nye issledovanija. 2013; 6-5: 1141–1145. (In Russ.).
- Samsygina G.A. Gerpes-virusnye infekcii u detej. Consilium Medicum. Pediatrija (Pril.). 2016; 2: 18–23, (In Russ.).
- Bortnikova V.V., Karabaeva V.V., Krepkova L.V. i dr. Flakozid – lekarstvennyj preparat iz list'ev barhata amurskogo, v terapii zabolevanij gepatobiliarnoj sistemy. Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2020; 2(23): 18–23. doi: 10.29296/25877313-2020-02-03 (In Russ.).
- Bortnikova V.V., Krepkova L.V., Karabaeva V.V. et al. Effectiveness of Flakozid Against Recurrent Genital Herpes Simplex Infections: Result of Clinical Trial. Clinical pharmacology in drug development. Аbstracts: 2020 Аnnual Meeting American College of Clinical Pharmacology®, September 21–23, 2020, USA. S2(9): 19–20. DOI: 10. 1002/срdd.858.
- Bortnikova V.V., Krepkova L.V. Jeksperimental'noe toksikologicheskoe izuchenie protivovirusnogo fitopreparata flakozid. Vestnik Rossijskogo universiteta druzhby narodov (RUDN). 2008; 7: 92–95 (In Russ.).
- Fateeva T.V., Deriabin P. G., Bortnikova V.V. et al. Experimental Study of Flakozid Activity in Viral Hepatitis C in vitro. Bulletin of Experimental Biology and Medicine. 2019; 4(167): 479–481. doi: 10.1007/s10517-019-04554-5.
- Vichkanova S.A., Kolhir V.K., Sokol'skaja T.A. i dr. Lekarstvennye sredstva iz rastenij. M.: ADRIS, 2009: 432 s. (In Russ.).
- Enioutina E.Y., Teng L., Fateeva T.V. et al. Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance. Expert Rev Clin Pharmcol. 2017; 11(10): 1203–1214. doi: 10.1080/17512433.2017.1371591.
Supplementary files
